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Abstract 
 
Purpose: To conduct a systematic review on measurement properties of questionnaires measuring depressive 
symptoms in adult patients with type 1 or type 2 diabetes. 
Methods: A systematic review of the literature in MEDLINE, EMbase and PsycINFO was performed. Full text, 
original articles, published in any language up to October 2016 were included. Eligibility for inclusion was 
independently assessed by three reviewers who worked in pairs. Methodological quality of the studies was 
evaluated by two independent reviewers using the COnsensus-based Standards for the selection of health 
 
Measurement INstruments (COSMIN) 
checklist. Quality of the questionnaires was rated per measurement property, based on the number and 
quality of the included studies and the reported results. 
Results: Of 6286 unique hits, 21 studies met our criteria evaluating 9 different questionnaires in multiple 
settings and languages. The methodological quality of the included studies was variable for the different 
measurement properties: 9/15 studies scored ‘good’ or ‘excellent’ on internal consistency, 2/5 on reliability, 
0/1 on content validity, 10/10 on structural validity, 8/11 on hypothesis testing, 1/5 on cross-cultural validity, 
and 4/9 on criterion validity. For the CES-D, there was strong evidence for good internal consistency, structural 
validity, and construct validity; moderate evidence for good criterion validity; and limited evidence for good 
cross-cultural validity. The PHQ-9 and WHO-5 also performed well on several measurement properties. 
However, the evidence for structural validity of the PHQ-9 was inconclusive. The WHO-5 was less extensively 
researched and originally not developed to measure depression. 
Conclusion: Currently the CES-D is best supported for measuring depressive symptoms in diabetes patients. 
 
 
 
Key words: diabetes, depression questionnaires, measurement properties, COSMIN checklist. 
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1 Abstract 
 
2 Purpose: To conduct a systematic review on measurement properties of questionnaires measuring depressive 
3 symptoms in adult patients with type 1 or type 2 diabetes. 
4 Methods: A systematic review of the literature in MEDLINE, EMbase and PsycINFO was performed. Full text, 
5 original articles, published in any language up to October 2016 were included. Eligibility for inclusion was 
6 independently assessed by three reviewers who worked in pairs. Methodological quality of the studies was 
7 evaluated by two independent reviewers using the COnsensus-based Standards for the selection of health 
8 Measurement INstruments (COSMIN) 
9 checklist. Quality of the questionnaires was rated per measurement 
10 property, based on the number and quality of the included studies and the reported results. 
11 Results: Of 6286 unique hits, 21 studies met our criteria evaluating 9 different questionnaires in multiple 
12 settings and languages. The methodological quality of the included studies was variable for the different 
13 measurement properties: 9/15 studies scored ‘good’ or ‘excellent’ on internal consistency, 2/5 on reliability, 
14 0/1 on content validity, 10/10 on structural validity, 8/11 on hypothesis testing, 1/5 on cross-cultural validity, 
15 and 4/9 on criterion validity. For the CES-D, there was strong evidence for good internal consistency, structural 
16 validity, and construct validity; moderate evidence for good criterion validity; and limited evidence for good 
17 cross-cultural validity. The PHQ-9 and WHO-5 also performed well on several measurement properties. 
18 However, the evidence for structural validity of the PHQ-9 was inconclusive. The WHO-5 was less extensively 
19 researched and originally not developed to measure depression. 
20 Conclusion: Currently the CES-D is best supported for measuring depressive symptoms in diabetes patients. 
20 
21 Key words: diabetes, depression questionnaires, measurement properties, COSMIN checklist. 
22 
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23 Introduction 
 
24 Diabetes is a common and serious chronic disease that is estimated to affect more than 350 million people 
25 worldwide [1]. Adult patients with diabetes type 1 or type 2 often have comorbid depression. Up to 20% of 
26 diabetes patients have major depressive disorder and up to 40% have clinically relevant depressive symptoms 
27 at one point in time according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders-IV 
28 (DSM-IV)[2-4]. 
29 Comorbid depression in patients with diabetes is associated with poorer adherence to medical treatment 
30 and more difficulties complying with self-care instructions compared to patients with diabetes alone [5]. These 
31 patients also experience adverse health outcomes, such as poorer glycemic control [6], more diabetes 
32 complications [7], lower quality of life [8] and higher risk of morbidity and all-cause mortality. Furthermore, 
33 they use more healthcare resources resulting in higher healthcare costs [9]. 
34 Given the high prevalence of co morbid depression and associated adverse health outcomes, it is important 
35 to monitor depressive symptoms in diabetes patients on a regular basis, for example to evaluate changes 
36 during and after an intervention. Clinical guidelines recommend doing this with standardized questionnaires 
37 [10]. This way, depression treatment can be optimized and adjusted when necessary [11]. 
38 A wide variety of questionnaires is available to measure depressive symptoms. Questionnaires that are 
39 frequently used in diabetic populations are the Center of Epidemiological Studies-Depression scale (CES-D) 
40 [12], the Hospital Anxiety and Depression Scale-Depression (HADS-D) [13], the Patient Health Questionnaire-9 
41 (PHQ-9) [14] and the Beck Depression Inventory-II (BDI-II)  [15]. However, these questionnaires generally assess 
42 symptoms of depression that may overlap with common symptoms of a medical illness such as diabetes (e.g., 
43 fatigue, changes in weight and appetite). Although many of these questionnaires have undergone extensive 
44 psychometric testing, an overview of their performance in this specific diabetes population is lacking [16]. This 
45 information is valuable because measurement properties may vary across populations. Also, a large number of 
46 questionnaires is available, while no recommendations are available which one to use to monitor depressive 
47 symptoms in diabetes patients. This makes it difficult to select the most suitable questionnaire for monitoring 
48 and evaluating depressive symptoms in diabetes patients. 
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49 Systematic, comparative evidence on the measurement properties of these questionnaires, used for 
50 evaluating depressive symptoms within patients on a continues scale, is required by physicians and 
51 researchers. 
52 Measurement properties are divided in three domains: reliability, validity and responsiveness [17]. A 
53 reliable questionnaire performs its measurements precisely, without too much measurement error. A valid 
54 questionnaire has the ability to measure the intended construct (and not something else). A responsive 
55 questionnaire is sensitive to changes in the construct to be measured [17]. Next to these three domains, it is 
56 important that a measurement instrument is interpretable, meaning that the quantitative results of the 
57 questionnaire can be translated to clinically meaningful conclusions [17]. 
58 Roy et al., conducted a comprehensive review in 2012  in which they identified frequently used depression 
59 questionnaires used in diabetes patients. They conclude the BDI, PHQ-9, CES-D and the HADS-D are most 
used. 
60 However, they did not systematically evaluate the measurement properties of the included questionnaires. It 
61 is therefore not known which questionnaire is most reliable and valid for measuring depressive symptoms in 
62 diabetes patients. Therefore, the aim of this study was to summarize the comprehensive research on the 
63 measurement properties (reliability, validity and responsiveness) of questionnaires used to evaluate 
64 depressive symptoms in adult patients with type 1 and type 2 diabetes. Knowledge generated from this study 
65 may help clinicians and researchers to make a better evidenced-based selection of questionnaires for the 
66 evaluation of depressive symptoms among diabetes patients. 
67 
 
68 Methods 
 
69 Design 
 
70 A systematic review of the literature was conducted according to the recommendations from the 
71 COnsensus-based Standards for the selection of health status Measurement INstruments (COSMIN) initiative 
72 (www.cosmin.nl). According to these recommendations the literature was systematically searched, the quality 
73 of the included studies was assessed, the results of the studies were rated against predefined criteria, the 
74 results of multiple studies per measurement property were systematically synthesized, and levels of evidence 
75 were applied. A detailed description of the used methods is provided below. 
76  
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77 Data sources, search strategy and study selection 
 
78 We searched MEDLINE, EMBASE, and PSYCINFO from inception (i.e., with no specified beginning date up 
79 until (and including)) to October 2016. The investigators developed the search after consulting an information 
80 specialist (a university librarian). The search strategy consisted of search terms for depression and type 1 and 
81 type 2 diabetes. Different from the COSMIN recommendations, terms regarding type of instrument and 
82 measurement properties (reliability, validity and responsiveness) were not used, because we wanted to reduce 
83 the chance of missing any relevant articles. The used search terms are shown in S1 Appendix. 
84 We included all studies published in any language on the measurement properties of self-report 
85 questionnaires measuring depressive symptoms (as defined as such by the authors of the paper)  in type 1 or 
86 type 2 diabetes patients (i.e. at least 80% of the study population had diabetes). Studies were included in the 
87 review when the questionnaire under study was used to measure depressive symptoms, even if the 
88 questionnaire was not originally developed for this purpose. Only studies that reported measurement 
89 properties of these questionnaires, i.e. reliability, validity and/or responsiveness, were included in the review. 
90 Studies that only assessed the diagnostic accuracy of a questionnaire were not included, since these studies 
91 are concerned with the ability of a questionnaire to detect a target condition, while in this review, the focus is 
92 on the evaluative use of questionnaires to monitor the severity of depressive symptoms over time. 
93 Three reviewers (SD, LZ, MA ) independently assessed the titles and abstracts of the retrieved studies to 
94 identify relevant studies. The reviewers worked in pairs and discussed their selection. When both reviewers 
95 agreed a study was possibly relevant or when consensus was not reached, the full text article was retrieved 
96 and read by all three authors to determine whether in- and exclusion criteria were met. For the final inclusion 
97 of an article, after reading of the full text,  consensus between all three reviewers (SD, LZ and MA) was 
98 needed. When consensus was not reached, a fourth reviewer decided (CT). The reference lists of the included 
99 articles were checked by two reviewers independently of each other (SD and LZ) and related citations of 
100 relevant articles found in MEDLINE were screened to identify additional relevant studies. 
101 
 
102 Identification of studied measurement properties 
 
103 Two reviewers (SD and LZ) independently identified for each study which measurement properties were 
104 reported. When no consensus was reached, a third reviewer discussed the interpretation of the reviewers with 
105   
106 them and decided based on her leading expertise in the field of measurement properties (CT). Based on the 
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107 COSMIN recommendations, three domains of measurement properties were distinguished: reliability, validity 
108 and responsiveness [17]. 
109 Reliability. A self-reported health questionnaire is considered reliable when it: a) is internally consistent, 
110 with all items (in a sub-scale) showing a high degree of interrelatedness (Cronbach’s α .70 - .90); b) has high 
111 reliability, which means that a high proportion of the variability in the measurement outcome is caused by real 
112 differences between or changes within patients;  and c) does not introduce a lot of measurement error 
113 (differences in the measurement outcome that cannot be attributed to differences in the construct to be 
114 measured [17]. 
115 Validity. Validity of a questionnaire includes: a) content validity, or how well a questionnaire reflects the 
116 construct it is supposed to measure; b) construct validity, or to which degree the measurement outcome 
117 reflects the dimensional structure of a questionnaire (structural validity), the degree to which the scores of a 
118 questionnaire are consistent with hypotheses based on theoretical knowledge of the construct to be measured 
119 (hypothesis testing) and the degree to which a translated questionnaire performs similarly to the original 
120 version (cross-cultural validity); and c) criterion validity, or how well the outcome of a questionnaire reflects 
121 the outcome of a ‘gold standard’ to measure the same construct [17]. 
122 Responsiveness. A questionnaire is considered responsive when it is able to detect change in the construct 
123 to be measured. 
124 Next to these three domains of measurement properties, it is important that the results of a questionnaire 
125 are interpretable [17]. 
126 
 
127 Assessment of the methodological quality of the included studies 
 
128 After consensus was reached on which properties were assessed in the selected studies, the 
129 methodological quality of the assessment of each studied measurement property was rated for all studies 
130 using the COSMIN checklist [18]. This checklist consists of 9 boxes that correspond with the defined 
131 measurement properties. In each box, methodological standards are presented on how each measurement 
132 property should be assessed. The 9 boxes consist of 5 (content validity) through 18 (hypothesis testing) items. 
133 These items are scored in a standardized way on a 4-point scale (i.e. “poor”, “fair”, “good” or “excellent”) [19]. 
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134 An overall score of the methodological quality for each box was determined by taking the lowest rating of any 
135 of the items in that box, since a low rating on any of the items signals a significant risk of bias. The quality 
136 assessment was independently done by three reviewers who worked in pairs (SD and LZ; SD and MA). These 
137 reviewers were trained by one of the developers of the COSMIN checklist (CT). A third reviewer (CT) decided 
138 when consensus on any item was not reached. 
139 
 
140 Data extraction 
 
141 Characteristics of the study design and questionnaires were extracted and summarized for all included 
142 studies. Study design characteristics included: questionnaire used, sample size, mean age, gender distribution, 
143 proportion of diabetes patients in the sample, country and setting in which the study was performed and 
144 language version of the used questionnaire. The following questionnaire characteristics were extracted: 
145 construct aimed to be measured, target population, number of items, subscales of the questionnaire, score 
146 range of the items and total scores, usual cut-points for depression, administration time and recall period. 
147 The results regarding the reported measurement properties were extracted by two reviewers (SD and LZ), 
148 independently. Results on the instrument quality were abstracted for every measurement property separately 
149 using a standardized data extraction form. We used common criteria to classify results as positive (good 
150 measurement quality of the questionnaire), inconclusive or negative (poor measurement quality of the 
151 questionnaire) [20]. The used criteria for quality of measurement properties  can be viewed in S2 Appendix. 
152 
 
153 Data synthesis 
 
154 To rate the overall quality of the questionnaires, we combined the results on each measurement property 
155 with the ratings of methodological quality in each box, the number of studies in which the measurement 
156 property was investigated and the consistency of the results. In the data synthesis only results of studies of 
157 excellent, good or fair methodological quality are considered, as recommended by the COSMIN initiative. An 
158 overall ‘level of evidence’ per measurement property was assigned to each individual questionnaire in 
159 accordance with previously performed systematic literature reviews [21,22]. As a result of this process, 
160 measurement properties were rated as positive, inconclusive or negative, with strong, moderate, limited or 
161 unknown level of evidence. In Table 1, the criteria used in this rating system are further explained. Although 
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162 questionnaires are often evaluated using different language versions and their measurement properties are 
163 not necessarily similar across countries, results were summarized for every questionnaire, regardless of 
164 language version because there were not enough data to study differences in measurement properties 
165 between language versions. The data synthesis was independently performed by two reviewers (SD and MT) 
166 and in case consensus was not reached, a third reviewer (CT) made a final decision taking the arguments of the 
167 other reviewers into account. 
168 
169 Table 1 - Criteria for assigning a level of evidence rating 
 
Level of evidence Rating Criteria 
Strong +++ or - - - Consistent findings in multiple studies of good methodological 
quality, or in one study of excellent methodological quality 
Moderate ++ or - - Consistent findings in multiple studies of fair methodological 
quality, or in one study of good methodological quality 
Limited + or - Evidence from one study of fair methodological quality 
Inconclusive +/- Inconclusive evidence 
Unknown ? Only studies of poor methodological quality 
170 Criteria were based on previously performed systematic reviews [22,21] 
 
171 
 
172 Results 
 
173 Search strategy, inclusion of relevant studies and studied questionnaires 
 
174 The search strategy yielded 6286 unique articles, of which 63 were selected based on title and abstract. 
175 After reading the full text version, 21 were eligible for inclusion. Searching related citations in MEDLINE and 
176 reference lists of included papers yielded no additional articles. Thus, in total, 21 relevant studies were 
177 included in this review [23-43]. The inclusion process is described in more detail in Fig 1. 
 
 
178 Fig 1 Selection of studies flowchart 
 
179 
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180 Nine different questionnaires were evaluated: the CES-D [12], the Chinese version of the Clinically Useful 
181 Depression Outcome Scale (CUDOS) [44], the Depressive Cognition Scale (DCS) [45], the Depression in Diabetes 
182 Self-Rating Scale (DDSRS) [27], the Edinburgh Depression Scale [46], the HADS-D [13], the McSad [47], the 
183 PHQ-9 [14] and the 5-item World Health Organisation Well Being Index (WHO-5) [48]. Information regarding 
184 the selected articles and the depression questionnaires is presented in Tables 2 and 3. 
185 
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186 Table 2 - Characteristics of the included studies 
 
Studies in alphabetic order Instruments Sample size Mean age in years 
(SD) 
Male (%) DM1/ DM2 
(% of total 
sample) 
Country in which 
study was 
performed 
Setting Language 
Awata et al. 2007 WHO-5 
129 
65 (criterion validity) 
54 (10) 55 16/84 Japan 
University 
hospital 
Japanese 
Carter et al. 2016 CES-D 305 56,9 (11.1) 45 1/100 Canada 
Rehabilitation 
institute 
English 
 
de Cock et al. 2011 
 
EDS 
 
1656 
 
65/67 (10/10.6)* 
 
50 
 
0/100 
 
The Netherlands 
 
Primary care 
 
Dutch 
Hajos et al. 2012 WHO-5 933 53.4 49 41/59 The Netherlands 
Hospital outpatient 
clinic 
Dutch 
Hsu et al. 2014 CUDOS 214 62.6 (13.2) 45 0/100 Taiwan 
University hospital 
outpatient clinics 
Chinese 
Janssen et al. 2016 PHQ-9 793 62.4 (7.7) 67 0/100 The Netherlands 
Community based 
sample 
Dutch 
Kokoszka 2008 DDSRS 101 63 (11) 50 0/100 Poland Medical University Polish 
 
Lamers et al. 2008 
 
PHQ-9 
365 (internal consistency, 
criterion validity) 
226 (hypothesis testing) 
27 (reliability) 
 
71 (6.9)** 
 
52** 
 
0/100 
 
The Netherlands 
 
Primary care 
 
Dutch 
Lehman et al. 2011 CES-D 151 56 (10) 46 0/100 Turkey 
University hospital 
outpatient clinics 
Turkish 
Lloyd et al. 2011 PHQ-9, WHO-5 24 55 50 0/100 
UK (Bangladeshi 
and Pakistani) 
Hospital outpatient 
clinic 
Sylheti, Mirpuri 
 
Papageorgiou et al.2013 
 
McSad 
 
114 
 
44 (14.1) 
 
22 
 
?/?*** 
 
The Netherlands 
Members of a 
diabetes patient 
organisation 
 
Dutch 
 
Rankin et al. 1993 
 
CES-D 
 
30 
 
range 46 thru 80 
 
57 
 
0/100 
 
United States 
 
Comprehensive 
health care centre 
 
Chinese 
Reddy et al. 2010 PHQ-9, HADS-D 
462 (PHQ-9) / 561 (HADS- 
D) 
70 55 0/100 Australia Primary care English 
 
Sousa et al. 2005 
 
DCS 
 
40 
 
29.25 (10.23) 
 
30 
 
?/?*** 
 
Brazil 
 
Convenience sample 
 
Portuguese 
Sousa et al. 2008 DCS 82 61.28 (11.37) 35 ?/?*** Brazil Primary care Portuguese 
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Stahl et al. 2008 
 
CES-D 
 
522 (internal consistency) 
291 (criterion validity) 
 
55(13) 
 
- 
 
3.5/96.5 
 
USA 
 
Hospital diabetes 
centre 
 
Chinese, Malay, 
Indian 
 
Sultan & Fisher 2010 
 
CES-D 
 
502 
 
53.6 (8.8) 
 
54 
 
0/100 
 
USA 
 
Community based 
sample 
 
English, Spanisch 
 
Zauszniewski et al. 2009 
 
CES-D 
 
80 
 
82 
 
30 
 
0/100 
 
USA 
 
Hospital 
 
English 
 
Zauszniewski & Graham 2001 
 
DCS 
 
83 
 
46 
 
0 
 
?/?*** 
 
USA 
 
Hospital 
 
English 
 
Zhang et al. 2013 
 
PHQ-9 
586 (internal consistency) 
40 (reliability) 
99 (criterion validity) 
 
55.1 (9.5) 
 
59 
 
0/100 
 
China 
Hospital outpatient 
clinic 
 
Chinese 
 
Zhang et al. 2015 
 
CES-D 
545 (internal consistency, 
structural validity) 
40 (reliability) 
97 (criterion validity) 
 
54.6 (9.5) 
 
59 
 
0/100 
 
China 
 
Hospital outpatient 
clinic 
 
Chinese 
 
CES-D, Centre for Epidemiological Studies Depression Scale; CUDOS, Clinically Useful Depression Outcome Scale; DCS, Depression Cognition Scale; DDSRS, Depression in Diabetes Self-Rating Scale; DM1, 
diabetes mellitus type 1; DM2, diabetes mellitus type 2; EDS, Edinburgh Depression Scale; HADS-D, Hospital Anxiety and Depression Scale - Depression; PHQ-9, Patient Health Questionnaire-9; SD, standard 
deviation; UK, United Kingdom; USA, United States of America; WHO-5 World Health Organization-Five Well-Being Index 
 
*Mean and standard deviation reported seperately for male/female participants 
** Characteristics of the total cohort in the study (not only diabetes patients) (N=713) 
*** No details were reported on the number of type 1 and type 2 diabetes patients. However, the total sample consisted of 100% diabetes patients (either type 1 or type 2). 
 
187 
188 
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189 Table 3 - Characteristics of the included questionnaires 
 
Name Construct aimed to 
be measured 
Target population # items Subscales Score range 
(item level) 
Score range 
(total) 
Usual cut points for 
depression** 
Administration Time 
(minutes) 
Recall Period 
CES-D Level of depressive 
symptomatology 
General population 20 NA 0-3 0-60 ≥16 5-10 minutes 1 week 
CUDOS Depressive 
symptoms 
General population 18 NA 0-4 0-72 0-10: no depression 
11-20: minimal 
21-30: mild 
31-45: moderate 
>45: severe 
3 minutes 1 week 
DCS Depressive 
cognitions 
Older adults 8 NA 0-5 0-40 ≥7* Not specified NA 
DDSRS Depressive 
symptoms 
Diabetes patients 6 NA 0-4 0-24 0-2    low severity* 
3-10 severe* 
11-24 high severity* 
<5 1 week 
EDS Depressive 
symptoms 
Originally: women, post 
natal 
Later: several different 
patient groups 
10 NA 0-3 0-30 0-8 not depressed 
9-11 minor depression 
≥12/13 major 
depression 
a few minutes 1 week 
HADS Depression/ Anxiety Hospital outpatients 14 
(7 in every 
subscale) 
Depression 
Anxiety 
0-3 0-42 (0-21 in 
every subscale) 
8-10 on depression 
subscale 
2-5 minutes 1 week 
McSad major unipolar 
depression for 
valuation purposes 
General population 6 
(1 per subscale) 
Emotion 
Self-appraisal 
Cognition 
Physiology 
Behavior 
Role function 
1-4 classification 
into one of 
4096 
descriptive 
profiles. 
In current study 
a total score of 
0-24 is used 
not specified a few minutes 1 week 
PHQ-9 Symptoms of major 
depressive disorder 
primary care patients 9 NA 0-3 0-27 0 - 4: no depression 
5 - 9: minimal 
10- 14: mild 
15 – 19: moderate 
≥ 20: severe 
Within minutes 2 weeks 
WHO-5 Emotional well- 
being (and later 
depression) 
General population 5 NA 0-5 0-25 ≤13 <5 minutes 2 weeks 
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CES-D, Centre for Epidemiological Studies Depression Scale; CUDOS, Clinically Useful Depression Outcome Scale; DCS, Depression Cognition Scale; DDSRS, Depression in Diabetes Self-Rating Scale; EDS, Edinburgh Depression 
Scale; HADS-D, Hospital Anxiety and Depression Scale - Depression; NA not applicable; PHQ-9, Patient Health Questionnaire-9; WHO-5 World Health Organization-Five Well-Being Index 
 
* no usual cut-off points specified, but cut off points resulted from analyses in included studies. 
 
190 
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191 Sample sizes of the included studies varied widely, ranging from 24 [30] to 1656 [24]. The population in 
192 which the questionnaires were assessed differs greatly regarding age, languages and settings. For example, 
193 mean age of the participants ranged from 29 [34] to 82 [39]. The questionnaires were assessed in 10 different 
193 languages (Japanese [23], Dutch[24,25,28,31,43], Chinese [26,32,37,40,41], Polish [27], Turkish [29], Sylheti 
194 [30], Mirpuri [30], English [33,37,36,38,39,42], Portuguese [35,34] and Spanish[36]). The setting in which the 
195 questionnaires were researched differed between studies (for example, primary care, hospital outpatient 
196 clinics, university hospitals and patient support group organizations). Most samples only consisted of type 2 
197 diabetes patients, but three studies also included type 1 diabetes patients [23,25,37]. Four studies did not 
198 specify the number of type 1 and type 2 diabetics [31,34,35,39]. 
199 
 
200 Methodological quality 
 
201 The methodological quality of the studies was variable ranging from ‘poor’ to ‘excellent’ (Table 4). 
202 Structural validity was rated as ‘good’ and ‘excellent’ for all studies. The most frequently assessed 
203 measurement properties were internal consistency (17 studies [23,25-29,32,33,35,34,37,36,39,40,38,41,43]) 
204 and hypothesis testing (13 studies [23,26-28,25,29,31-33,35,36,39,38]). Only few studies examined reliability 
205 (5 studies) [26,28,40,41,33], cross cultural validity (5 studies) [34,30,23,26,32] and content validity (1 study) 
206 [30]. There were no studies that examined measurement error, responsiveness or interpretability. 
207 
208 
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209 Table 4 - Methodological quality of the included studies per measurement property 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
210 CES-D, Centre for Epidemiological Studies Depression Scale; CUDOS, Clinically Useful Depression Outcome Scale; DCS, Depression Cognition Scale; 
211 DDSRS, Depression in Diabetes Self-Rating Scale; EDS, Edinburgh Depression Scale; HADS-D, Hospital Anxiety and Depression Scale - Depression; 
212 PHQ-9, Patient Health Questionnaire-9; WHO-5 World Health Organization-Five Well-Being Index. 
213 
214 Two out of 15 studies scored ‘excellent’ [25,33] and seven studies scored ‘good’ [23,26,29,35,36,38,39] on 
215 internal consistency, Lower quality ratings were mostly caused by not assessing or describing the 
216 dimensionality of a questionnaire and not assessing internal consistency for every sub-scale of a questionnaire 
217 separately [28,40,32,37,27,41,43], or having a small or not representative study population [34,32]. 
218 Five studies assessed the reliability of the investigated questionnaire, of which one study was rated 
219 ‘excellent’ [33] and one study was rated ‘good’ [26]; the other three studies were of poor methodological 
220 quality [28,40,41] due to flaws in the study design or statistical methods used. 
221 One study [30] reported content validity and was rated ‘poor’ due to methodological flaws in the design of 
222 the study. Of the ten studies reporting structural validity [23-26,29,33,35,36,41], two were rated ‘excellent’ 
223 [25,33] and the other eight studies were rated ‘good’. The difference between a ‘good’ or ‘excellent’ rating 
Publication Used 
questionnaire 
Internal 
consistency 
Reliability Content 
validity 
Structural 
validity 
Hypotheses 
testing 
Cross 
cultural 
validity 
Criterion 
validity 
Awata et al. 2007 WHO-5 good   good fair fair poor 
Carter et al 2016 CES-D    good    
De Cock et al. 2011 EDS    good    
Hajos et al. 2012 WHO-5 excellent   excellent good  poor 
Hsu et al. 2014 CUDOS good good  good fair fair fair 
Janssen et al 2016 PHQ-9 poor   good   good 
Kokoszka 2008 DDSRS poor    poor  poor 
Lamers et al. 2008 PHQ-9 poor poor   fair  good 
Lehhman et al. 2011 CES-D good   good good   
Lloyd et al. 2011 PHQ-9/WHO-5   poor   poor  
Papageorgiou et al. 2013 McSad      excellent   
Rankin et al. 1993 CES-D poor    poor fair  
Reddy et al. 2010 PHQ-9/HADS-D  excellent  excellent good   
Sousa et al. 2005 DCS fair     good  
Sousa et al. 2008 DCS good   good good   
Stahl et al. 2008 CES-D poor      fair 
Sultan & Fisher 2010 CES-D good   good good   
Zausniewski et al. 2001 CES-D good    good   
Zausniewski & Graham, 2009 DCS good    good   
Zhang et al. 2013 PHQ-9 fair poor     good 
Zhang et al. 2015 CES-D poor poor  good   good 
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224 was caused by differences in reporting on missing values and drop-out in the study, or differences in sample 
225 size, with excellent studies having a larger sample. 
226 One out of 11 studies reporting hypothesis testing was rated ‘excellent’ [31]. Seven studies were rated 
227 ‘good’ [25,29,33,35,36,39,38]. The main reasons for a lower quality score were small sample size [32,28] or 
228 not sufficiently specifying prior hypotheses [23,26,27]. 
229 Of the 5 studies assessing cross-cultural validity, one study was rated ‘good’ [34]. Lower quality scores were 
230 mainly caused by flaws in the translation process, not testing the translation in patients with diabetes before 
231 using the questionnaire in this population [32,26,23] and small sample size [30]. 
232 Nine studies assessed criterion validity; four of these studies scored ‘good’ [28,40,41,43]. The main reasons 
233 for a poor or fair rating were not using an accurate reference standard for measuring depression [25,27], flaws 
234 in the study design [27,23] or using a case control design without correction [23], thereby inflating estimates 
235 of criterion validity [49]. None of the studies were rated excellent because no gold standard exists to measure 
236 depression. 
237 
 
238 Measurement properties of questionnaires measuring depressive symptoms 
 
239 Table 5 summarizes all results on measurement properties for each questionnaire. The final judgment on 
240 the level of evidence for the quality of the questionnaires per measurement property is presented in Table 6. 
241 Since none of the studies assessed measurement error, responsiveness or interpretability, these properties are 
242 not included in the tables. 
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Table 5 - Results of all assessments of measurement properties, organized by questionnaire 
 
 
questionnaire 
 
study 
 
version used 
 
internal consistancy (95% 
CI) 
 
reliability 
(95% CI) 
 
content 
validity 
structural validity 
(% variance 
explained) 
 
hypothesis testing 
 
cross cultural validity 
criterion validity 
used 
reference 
Pearson's r 
AUC 
(95% CI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CES-D 
 
 
Carter et al. 
2016 
 
14-item CES-D as 
proposed by Carleton 
et al. (2013) 
   3 factors, (8.3%) one 
General factor, 
(87%) 
factor 1 PA 
factor 2 NA 
factor 3 SS 
     
 
Lehman et al. 
2011 
 
full CES-D Turkish 
factor 1: 
Cronbach’s α .90 
factor 2: 
Cronbach’s α .82 
  
2 factors, (n.r) 
factor 1 NA* 
factor 2 (PA)* 
convergent validity**: 
WHO-5: r -.45 - r -.70 
PAID r .17 - r .45 
    
 
Rankin et al. 
1993 
 
full CES-D Chinese 
 
Cronbach's α .92 
   convergent validity***: 
PPS r .57 
SPS r .38 
DQLS r .52- .59 
Translation 
comprehensible and 
adequate 
   
 
Stahl et al. 2008 
full CES-D Chinese 
full CES-D Malay 
full CES-D Indian 
Cronbach's α .72 
Cronbach's α .70 
Cronbach's α .79 
      
SCAN 
 
n.r 
.82 (n.r) 
.64 (n.r) 
.82 (n.r) 
 
Sultan & Fisher 
2009 
 
full CES-D English 
full CES-D Spanish 
factor 1: 
Cronbach’s α .90 
factor 2: 
Cronbach’s α .67 
   
2 factors (55%) 
factor 1 NA* 
factor 2 PA* 
factor 1 associated with 
disease severity (β = .113) 
factor 2: associated with 
disease severity (β =-.100) 
    
Zauszniewski & 
Graham 2009 
 
full CES-D English 
 
Cronbach's α .87 
   r .98- r .82** (full version 
with 12 short forms) 
    
 
 
Zhang et al. 2015 
 
 
Full CES-D Chinese 
 
 
Cronbach’s  α .85 
 
Pearson's r 
.64 
 4 factors (61%) 
factor 1 NA 
factor 2 SS 
factor 3 PA 
factor 4 IP 
   
 
MINI 
 
 
n.r 
 
 
.85 (.77-.92) 
 
 
CUDOS 
 
 
Hsu et al. 2014 
 
 
CUDOS Chinese 
 
 
Cronbach's α 
.66 -.83  for the 4 factors 
 
 
ICC .92 (n.r) 
  
 
4 factors, (n.r) 
convergent validity***: 
BDI: r subscales .71-.87 
group contrast 
MD+ vs MD-: mean 
difference 17.5 (p< 0.001) 
 
Translation 
comprehensible and 
adequate 
 
 
DSM-IV (not 
specified) 
 
 
n.r 
 
 
.84 (.77-.90) 
 
 
DCS 
 
Zauszniewski et 
al. 2001 
 
full DCS English 
 
Cronbach's α .85 
   
1 single factor (51%) 
convergent validity****: 
BDI r=0.73 
SCS r=-0.55 
HPLP II r=-0.51 
    
 
Sousa et al. 2005 
 
full DCS Portuguese 
 
Cronbach's α .79 
    performance 
comparable with 
English version in 
bilingual patients 
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Sousa et al. 2008 
 
full DCS Portuguese 
 
Cronbach's α .88 
   
1 single factor (57%) 
convergent validity****: 
BDI r .24 
    
 
DDSRS 
 
Kokoszka 2008 
 
full DDSRS Polish 
 
Cronbach's α .81 
   
67% - ≤80% 
concurrence BDI + HDRS 
 BDI 
HDRS 
HADS-D 
r .72 
r .68 
r .68 
 
n.r 
EDS 
de Cock et al. 
2011 
full EDS Dutch 
   
1 single factor (n.r) 
     
 
HADS-D 
Reddy et al. 
2010 
 
full HADS-D English 
 
Cronbach's α .83 
   
1 single factor (50%) 
convergent validity****: 
PHQ-9:  r .78 
    
 
 
McSad 
 
 
Papageorgiou et 
al., 2013 
 
 
full McSad Dutch 
    convergent validity***: 
CES-D r .50 - r .70 
PHQ-9 r .65 - r .76 
divergent validity***: 
self-esteem r .32 - r .48 
extraversion r .21 - r .31 
    
 
 
 
 
 
 
 
 
PHQ-9 
Janssen et al. 
2016 
 
full PHQ-9 Dutch 
 
Cronbach's α .87 
  2 factors (n.r) 
Factor 1: SS 
Factor 2: NS 
   
MINI 
 
n.r. 
 
.87 (n.r) 
 
Lamers et al. 
2007 
 
 
full PHQ-9 Dutch 
 
 
Cronbach's α .80 
 
Pearson's r 
.91 
  convergent validity** 
SF-36 mental health r -.58 
DSC-R r -.39 
Divergent validity** 
SF-36 subscales r .30 - r. 50 
  
 
MINI 
 
 
n.r. 
 
 
.92 (.92-.93) 
 
Lloyd et al. 2011 
 
full PHQ-9 Sylheti, full 
PHQ-9 Mirpuri 
  Good, 
based on 
focus 
group 
  
culturally acceptable 
translations were 
reached 
   
Reddy et al. 
2010 
full PHQ-9 English Cronbach's α .90 
  
1 single factor (57%) 
convergent validity **** 
HADS-D:  r .78 
    
Zhang et al. 2013 full PHQ-9 Chinese Cronbach's α .86 
Pearson’s r 
.70 
    
MINI n.r .85 (.76- .94) 
 
 
 
 
 
 
 
 
WHO-5 
 
 
 
Awata et al. 
2007 
 
 
 
 
full WHO-5 Japanese 
 
 
 
 
Cronbach's α .93 
   
 
 
 
1 single factor (71%) 
convergent validity***: 
SDS r .68 
STAI r .73- .74 
SF-36 subscales r .39- r .72 
Divergent validity*** 
Cognitive Functionning r .11 
educational level r .03 
medical outcomes r -.21- r 
.10 
 
 
high level of item 
acceptability and 
comprehension of the 
translated version of 
the WHO-5 Japanese 
 
 
 
 
SCID-I 
 
 
 
 
n.r 
 
 
 
 
.92 (.85- .98) 
 
Hajos et al. 2012 
 
full WHO-5 Dutch 
 
DM2: Cronbach's α .91 
DM1: Cronbach's α .95 
   
1 single factor (n.r) 
1 single factor (n.r) 
convergent validity***: 
PHQ-9: r .67 (DM2) r .69 
(DM1) 
  
PHQ-9 ≥ 10 
PHQ-9 ≥ 12 
 
n.r 
 
.91 (.98- .94) 
.89 (.87-.92) 
 
Lloyd et al. 2011 
 
full WHO-5 Sylheti 
full WHO-5 Mirpuri 
  Good, 
based on 
focus 
group 
  
Culturally acceptable 
translations were 
reached 
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243 5% CI= 95% Confidence Interval; AUC, area under the curve; BDI, Beck Depression Inventory; CES-D = Centre for Epidemiological Studies Depression Scale; cog., cognitive; CSDD, Scale for the Diagnosis of Depression; CUDOS, Clinically Useful 
244 Depression Outcome Scale; DCS, Depression Cognition Scale; DDSRS, Depression in Diabetes Self-Rating Scale; DM1, Diabetes Mellitus type 1; DM2, Diabetes Mellitus type 2; DQLS, Diabetes Quality of life Scale; DSC-R Diabetes Symptom Checklist- 
245 Revised; DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth edition; EDS, Edinburgh Depression Scale; HDRS, Hamilton Depression Rating Scale; HADS-D, Hospital Anxiety and Depression Scale- Depression; HPLP-2, Health 
246 Promoting Lifestyle Profile-II; ICC, Intra Class Correlation; IP, Interpersonal Problems; n.r., not reported; MD, Major Depression; MINI, Mini International Neuropsychiatric Interview; MSA, Mokken Scale Analysis; NA, Negative Affect; n.r., not 
247 reported; NS, Non-somatic Symptoms; PA, Positive Affect; PAID, Problem Areas in Diabetes; PCA, Principal Component Analysis; PHQ-9, Patient Health Questionnaire; PPS, Pscychological Problems Scale; SCAD, Silverstone Concise Assessment for 
248 Depressio ; SCAN Scedules for Clinical Assessment in Neuropsychiatry; SCID, Structured Clinical Interview for DSM; SCS, Self-Control Schedule; SDS, Zung’s Self Rating Depression Scale; SF-36, Medical Outcomes study 36-item Short Form Health 
249 Survey; SPS, Social Problems Scale; SS, somatic symptoms; STAI, State-Trait Anxiety Inventory; WHO-5 World Health Organization-Five Well-Being Index 
250 
251 * Eigenvalue factor 1 (negative affect): 7.345, factor 2 (positive affect) 2.249 
252 ** Pearssons's correlation coefficient 
253 ***Spearman's correlation coefficient 
254 **** Type of correlation coefficient not reported 
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255 
 
256 
257 
258 
259 
260 
261 
262 
263 
264 
265 
266 
267 
268 
269 
270 
271 
 
 
 
276 
277 
278 
279 
280 
281 
282 
283 
284 
285 
Table 6 - Levels of evidence for the quality of the questionnaires 
 
 
 
 
Internal 
consistency 
 
Reliability 
 
Content validity 
 
Structural validity 
Hypothesis 
testing 
Cross-cultural 
validity 
 
Criterion validity 
CES-D 
 
+++ 
 
NA 
 
NA 
 
+++ 
 
+++ 
 
+ 
 
++ 
CUDOS 
 
++ 
 
++ 
 
NA 
 
- - 
 
+ 
 
+ 
 
+ 
DCS +++ NA NA +++ +/- ++ NA 
DDSRS ? NA NA NA ? NA ? 
EDS NA NA NA ++ NA NA NA 
HADS +++ NA NA +++ ++ NA NA 
McSad NA NA NA NA +++ NA NA 
PHQ-9 +++ ? ? +/- ++ ? 
272 
+++  
273
 
WHO-5 +++ ? ? ++ ++ + ?    274 275 
+++ = strong positive evidence; 
++ = moderate positive evidence; 
+ = limited positive evidence; 
--- = strong negative evidence; 
- - = moderate negative evidence; 
+/- = inconclusive; 
? = unknown, due to poor methodological quality; 
NA = no information available 
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286 CES-D. The CES-D was assessed in six different languages in six studies [29,32,37,36,39,41]. For internal 
287 consistency, structural validity, hypothesis testing, cross-cultural validity and criterion validity, there is 
288 predominantly strong to moderate evidence for good performance of the CES-D. Although not all studies 
289 assessing structural validity found the same factor structure, the two dominant factors (positive affect and 
290 negative affect) were found in every study [41,36,29,42]. The additional factors found by Zhang et al [41] and 
291 Carter et al[42]  all correlate highly with the negative affect factor. Therefore, we consider the evidence on 
292 structural validity consistent. One study evaluated reliability, but was of poor methodological quality [41] 
293 Therefore, it was not possible to draw conclusions about the reliability of the CES-D. 
294 CUDOS. The measurement properties of the CUDOS-Chinese were assessed in one study [28]. Results for 
295 internal consistency, reliability, structural validity, hypothesis testing and criterion validity were available. For 
296 internal consistency, inconsistent findings on four subscales resulted in inconclusive evidence. In confirmatory 
297 factor analysis, four subscales were found, and as far as we know current literature does not support the 
298 existence of four sub-scales in the depression construct. Therefore, structural validity was considered poor, 
299 with moderate evidence supporting this finding. Reliability, construct validity (hypothesis testing) and criterion 
300 validity were good for the CUDOS-Chinese, with moderate to limited evidence for these findings. 
301 DCS. The DCS was evaluated in three different studies, using two different languages (English and 
302 Portuguese) [38,34,35]. There was strong evidence for good internal consistency and structural validity. One 
303 study showed moderately strong evidence of good cross-cultural validity of the Portuguese translation of the 
304 DCS [34]. Hypothesis testing resulted in inconclusive findings. Reliability, measurement error, content validity, 
305 responsiveness and interpretability were not assessed. 
306 EDS. Only one study [24] assessed a Dutch version of the EDS. Within this study only structural validity was 
307 assessed. Since this was done with good methodological quality and the analysis yielded one single, 
308 theoretically explicable factor, evidence regarding structural validity was considered moderate for good 
309 structural validity. 
310 HADS-D. One single study [33] assessed measurement properties of the HADS-D. There was strong 
311 evidence for good internal consistency and structural validity and moderate evidence for good construct 
312 validity (hypothesis testing). 
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313 McSad. The construct validity of the Dutch McSad was evaluated in one study using hypothesis testing [31]. 
314 The methodological quality of this assessment was rated excellent, resulting in confirmation of all pre-set 
315 hypothesis. The level of evidence was therefore rated ‘strong’ for good construct validity. 
316 PHQ-9. Measurement properties of the Patient Health Questionnaire (PHQ) were assessed in five different 
317 studies in five different languages [28,30,33,40,43]. Reliability, content validity, cross cultural validity, internal 
318 consistency, structural validity and criterion validity were assessed. However, assessments of reliability, 
319 content validity and cross cultural validity were not included in the data synthesis, since these were of poor 
320 methodological quality. There was strong evidence of good internal consistency and criterion validity. 
321 Construct validity (hypothesis testing) was rated ‘good’ with a moderate level of evidence. The evidence for 
322 structural validity was inconclusive, since two studies of at least good quality found different factor structures 
323 [43,33]. 
324 WHO-5. Measurement properties of the WHO-5 were assessed by three different studies in four different 
325 languages [23,25,30]. Reliability, measurement error, responsiveness and interpretability were not assessed 
326 and the assessments of content validity and criterion validity were of poor methodological quality. Internal 
327 consistency was good, with strong level of evidence. Evidence for good structural validity and construct validity 
328 (hypothesis testing) was moderate. There was limited evidence for good cross cultural validity of the WHO-5 
329 [23]. 
330 
 
331 Discussion 
 
332 We identified 21 studies evaluating the measurement properties of nine different questionnaires for 
333 measuring depressive symptoms in diabetes patients. Overall, the CES-D performed best, with strong evidence 
334 for a positive internal consistency, structural validity, and construct validity, moderate evidence for a positive 
335 criterion validity  and limited evidence for positive cross-cultural validity. Insufficient information was available 
336 on content validity and reliability. 
337 The use of the WHO-5 was supported by strong evidence for a positive internal consistency and moderate 
338 evidence for a positive structural validity and construct validity. However, the WHO-5 is originally developed as 
339 a questionnaire to measure the level of emotional well-being and not to assess depressive symptoms. Yet, 
340 caution should be applied when choosing the WHO-5 to specifically measure depressive symptoms. The PHQ-9 
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341 is frequently studied amongst patients with diabetes. We found strong evidence for a positive internal 
342 consistency and positive criterion validity and moderate evidence for positive construct validity. However, 
343 since the evidence for its structural validity is inconclusive, caution should be applied when the PHQ-9 is used 
344 for evaluative purposes. For all other questionnaires, evidence is too limited to draw any definitive conclusions 
345 regarding their measurement properties. Therefore, based on the current evidence we recommend using the 
346 CES-D for evaluating depressive symptoms in patients with diabetes. However, for none of the questionnaires 
347 complete information is available on all measurement properties when used in a population of adults with 
348 diabetes. One important shortcoming is lack of evidence on the content validity of the questionnaires, 
349 including the CES-D, in diabetes patients. Content validity is often considered the most important 
350 measurement property because it can affect all other measurement properties. Therefore, we recommend 
351 further literature review on the content validity of these questionnaires in other populations, as well as 
352 qualitative studies with patients and professionals on the relevance, comprehensiveness, and 
353 comprehensibility of these questionnaires in diabetes patients. Furthermore, measurement error, 
354 responsiveness and interpretability were not assessed for any of the questionnaires. This is important since 
355 shortcomings in any of the measurement properties pose a considerable threat to the ability of a 
356 questionnaire to measure depression in diabetes patients [50]. 
357 Our systematic review adds to the current literature by providing a structured and comprehensive 
358 overview of the measurement properties of depression questionnaires used in diabetes patients and the 
359 methodological quality of the studies assessing them. Also, this review provides recommendations on their 
360 use. By describing which questionnaires are – at this point in time - best supported by the evidence, this 
361 review is of use when choosing a questionnaire to monitor depression in daily practice. 
362 Previously, Roy et. al., (2012) conducted a comprehensive review of depression screening questionnaires and 
their operating 
363 characteristics in diabetes populations [16]. In their review, 23 relevant studies were identified. There is only 
364 limited overlap in studies (n=5) between the study of Roy et al., and our review. This is mainly because we 
365 included studies that assessed measurement properties of questionnaires used to evaluate depressive 
366 symptoms (for evaluative purposes), and we excluded studies assessing diagnostic test accuracy of 
367 questionnaires used for screening or detecting a depressive disorder. Roy et al. concluded that there is lack of 
368 evidence on the reliability and validity of depression questionnaires used for patients with diabetes to provide 
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369 recommendations. In our more recent and up-to-date review more evidence was available to provide 
370 recommendations for measuring change in depressive symptoms. 
371 Other reviews assessing the use of depression questionnaires in patients with chronic medical illnesses (for 
372 example, in patients with cancer [51] and Parkinson’s disease [52]) provided comparable recommendations, 
373 suggesting that our findings are robust. However, we are aware that we need to be cautious in recommending 
374 the use of the CES-D because of the lack of evidence on some important measurements properties, like 
375 reliability and responsiveness. 
376 A new development in measuring and monitoring patient-reported health is the use of item banks based 
377 on Item Response Theory (IRT), such as those from the Patient Reported Outcomes Measurement Information 
378 System (PROMIS)(www.healthmeasures.net/promis). IRT-based item banks enable Computer Adaptive Testing 
379 (CAT), in which, after a starting question, the computer selects subsequent questions based on the answers to 
380 previous questions. With CAT patients need to complete on average only 5-9 questions to get a reliable score, 
381 which makes this method a highly efficient and patient-friendly way of measuring. The PROMIS Depression 
382 instruments seem to be valid and reliable for measuring depressive symptoms [53,54]. Recent studies indicate 
383 that the PROMIS Depression CAT can be more easily used in clinical practice than the CES-D and PHQ-9 since it 
384 can be adapted to the needs in a specific care setting, while it results in comparable scores [55-57]. The 
385 PROMIS methodology is promising for use in patients with a chronic physical illness, minimizing the impact of 
386 somatic symptoms on depression scores while retaining enough uniformity to compare between patient 
387 populations and other depression measures [57]. Therefore, in time, PROMIS might replace the traditional 
388 depression questionnaires. 
389 This study is the first to systematically summarize the evidence on the measurement properties of 
390 questionnaires measuring depressive symptoms in patients with diabetes. A strength of this study is the use of 
391 the standardized COSMIN methodology for critical appraisal of the methodological quality of these studies, the 
392 quality of the questionnaires and the level of evidence. Another strength of this review is its inclusive search 
393 strategy, thereby limiting chances of missing important studies. 
394 The following two limitations apply. Firstly, the identified depression questionnaires were assessed in a 
395 large variety of languages and settings, but whether the results on the individual questionnaires discussed in 
396 this review can be validly generalized across language versions is not clear. Only few identified studies 
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397 performed a cross-cultural validation of translated questionnaires in a diabetes population. Questionnaires 
398 may perform differently across different languages and cultures [21]. 
399 Secondly, to provide a comprehensive overview of measurement properties of depression questionnaires 
400 in diabetes patients, we deliberately excluded studies that only assessed diagnostic accuracy.  Although this 
401 distinction is based on a theoretically sound concept and rests on differences in the use and purpose of a 
402 questionnaire (monitoring versus diagnosing), in the various studies, this distinction was often not clearly 
403 made. This resulted in some difficulties deciding whether or not a study should be included in the review. 
404 Further studies are needed on the measurement properties of depression questionnaires in diabetes 
405 patients. The finding that internal consistency, hypothesis testing and structural validity are the most 
406 evaluated properties is in line with other literature [22,58,59] However, not  all measurement properties 
407 (measurement error, responsiveness and interpretability) are extensively evaluated and further research is 
408 needed to provide definitive recommendations. 
409 In summary, this systematic review constitutes an important knowledge base for health care providers and 
410 researchers by providing a comprehensive overview of questionnaires measuring depressive symptoms in 
411 diabetes patients. The CES-D has the strongest evidence for good measurement properties for measuring 
412 depressive symptoms in patients with diabetes. 
413 
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